NCT00020878

Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers

Celecoxib for Chemoprevention of Primary Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Jonsson Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Celecoxib may be effective in preventing lung cancer in tobacco smokers. PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing non-small cell lung cancer in tobacco smokers.

Detailed description

OBJECTIVES: * Determine the efficacy and feasibility of celecoxib for chemoprevention of primary non-small cell lung cancer in high-risk tobacco smokers. * Determine the safety and long-term side effects of this drug in this population. OUTLINE: Patients receive oral celecoxib twice daily for 6 months. Patients are followed at 2 weeks and then at 6 months. PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 6 months.

Conditions

• Lung Cancer

Interventions

Type	Name	Description
DRUG	celecoxib	Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.

Timeline

• Start date: 2001-03-01
• Primary completion: 2002-11-01
• Completion: 2009-05-01
• First posted: 2003-01-27
• Last updated: 2020-08-03

Locations

1 site across 1 country: United States